NCT05672147
CD33-CAR T Cell Therapy for the Treatment of Recurrent or Refractory Acute Myeloid Leukemia
At risk: Primary completion moved 3 years later.
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 8 versions: 7 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Notable Primary and study completion pushed from Sep 3, 2028 to Sep 3, 2031
- Eligibility criteria expanded, about 23 words
- Secondary endpoints: details revised at 2 of 5 entries
- Study description revised
- Notable Primary and study completion dates: Sep 3, 2026 to Sep 3, 2028v6
- Minor Start date changed from estimate of Dec 28, 2023 to Dec 7, 2023v5
- Notable Primary and study completion dates: Nov 13, 2025 to Sep 3, 2026
- Start date: Nov 1, 2023 to Dec 28, 2023
- Notable Start date: Aug 13, 2023 to Nov 1, 2023v3
- Notable Trial status: Not Yet Recruiting to Recruiting
- Start date: May 13, 2023 to Aug 13, 2023
- Site details revised
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Participants who achieve measurable residual disease (MRD)
Timeframe: Up to 15 years post study treatment
Incidence of dose-limiting toxicities and full toxicity profile
Timeframe: Up to 1 year following the last CAR T cell infusion
Secondary (5)
Expansion and persistence of the CAR T cell product
Percent and counts from peripheral blood cell subsets in hematopoietic stem/progenitor cell compartments
Duration of response
Progression-free survival
Overall survival
Arms and interventions
Treatment (anti-CD33 CAR T-cells)Experimental
Patients undergo lymphodepletion therapy 3-5 days prior to CAR T cell infusion and receive anti-CD33 CAR T-cells IV on day 0. Patients with persistent CD33+ AML who are \> 28 days past the initial CAR T infusion, have additional product available and did not experience a dose-limiting toxicity, may optionally receive anti-CD33 CAR T-cells IV.
Biologicals: Anti-CD33 CAR T-cells
Procedures: Lymphodepletion Therapy
Sites
1 site in 1 country
- City of Hope Medical CenterDuarte, California, United States